Earth Science Tech, INC 10-Q quarterly reports

Earth Science Tech, Inc. announced its Q2 2026 results, showcasing a 3% revenue increase and a significant rise in net income, driven by operational efficiencies and strategic investments.

Earth Science Tech, Inc. announced significant revenue and net income growth for the nine months ended December 31, 2025, alongside strategic acquisitions and a strengthened balance sheet.

Earth Science Tech, Inc. reported a 4% increase in revenue for the six months ended September 30, 2025, reaching $17.8 million, while net income attributed to shareholders decreased by 25% to $1.43 million.

Earth Science Tech, Inc. reported a significant drop in net income for Q1 2025 despite a slight revenue increase, driven by higher operating expenses and lower gross margins.

Earth Science Tech, Inc. reports a significant increase in revenue for the quarter ended December 31, 2024, driven by strategic acquisitions and expanded operational capabilities.

Earth Science Tech, Inc. reports a significant increase in revenue for the quarter ended December 31, 2024, driven by strategic acquisitions and expanded operational capabilities.

Earth Science Tech, Inc. reports a significant increase in revenue and profitability for the quarter ended September 30, 2024, driven by strong pharmaceutical sales.

Earth Science Tech, Inc. reports a significant increase in revenue and a shift to profitability in the first quarter of fiscal year 2025, primarily driven by its pharmaceutical and telemedicine subsidiaries.

Earth Science Tech, Inc. reports a significant increase in revenue and profitability for the quarter ended December 31, 2023, primarily due to the acquisition of RxCompound and Peaks.